On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...